Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash & Current Investments: 2010-2025

Historic Cash & Current Investments for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $19.5 million.

  • OptimizeRx's Cash & Current Investments rose 2104.06% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 2104.06%. This contributed to the annual value of $13.4 million for FY2024, which is 340.75% down from last year.
  • Per OptimizeRx's latest filing, its Cash & Current Investments stood at $19.5 million for Q3 2025, which was up 2104.06% from $16.6 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Cash & Current Investments ranged from a high of $89.0 million in Q1 2022 and a low of $13.4 million during Q4 2024
  • Moreover, its 5-year median value for Cash & Current Investments was $63.5 million (2023), whereas its average is $52.2 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 70520.66% in 2021, then tumbled by 8131.69% in 2023.
  • OptimizeRx's Cash & Current Investments (Quarter) stood at $84.7 million in 2021, then fell by 12.45% to $74.1 million in 2022, then crashed by 81.32% to $13.9 million in 2023, then decreased by 3.41% to $13.4 million in 2024, then surged by 45.88% to $19.5 million in 2025.
  • Its last three reported values are $19.5 million in Q3 2025, $16.6 million for Q2 2025, and $16.6 million during Q1 2025.